Merck in $300m Immune Design boost for Keytruda
Announced today, the deal sees Merck pay $5.85 per share to acquire Immune Design and its portfolio of late-stage immunotherapies.
Top Headlines
Global Industry News
-
Solving pharma’s ‘big text’ problem with NLP
from Outsourcing-Pharma.com
-
Sites challenged with fragmented processes that ‘drain resources’
from Outsourcing-Pharma.com
-
ATS harnesses electromagnetic technology for cell minimizing unit
from BioPharma-Reporter.com
-
WuXi Biologics expects to receive EU GMP nod in matter of months
from BioPharma-Reporter.com
Hot Topics
-
European manufacturing waiver to ‘level the playing field’
Globalisation
-
Lonza utilizes global network for CBD-based drug manufacture
Bioavailability Challenge
-
FDA seeks transparent relationship on manufacturing standards
Lifecycle Management
-
With medicine tracking operational, what does this mean for industry?
Globalisation
